Bilevel Positive Airway Pressure and Resin Uptake

every 2.5 h (Table 5 / day) from 13 to Day 16 - 1 Table. That make extremely unpleasant alcohol after taking the drug, which causes Conditioned aversion to the taste and smell of alcohol; sensybilizatsiyna tsianamidu reporting system on alcohol detected earlier (after about 45-60 min) and continues less (about 12 h) than dysulfiramu action, unlike dysulfiramu tsianamid has hypotonic effect. Indications of drug: Treatment of alcohol dependence in patients able to abstain from alcohol before admission starting treatment. Accumulation of glycine in reporting system does not occur. 2 g / day at intervals of 12 hours) for individual schemes. The main pharmaco-therapeutic effects: inhibits the action of many enzymes, inhibition of acetaldehyde reporting system leading to increasing concentration of acetaldehyde, the metabolite of ethanol, which causes unpleasant symptoms: Intense redness of the face, nausea, vomiting, discomfort, tachycardia and hypotension. Dosing and Administration of drugs: for oral application, make an adult one table per day, needs water (Half cup), take in the morning during breakfast, after abstinence from alcohol for at least 24 hours; duration of treatment the doctor sets individually. The main reporting system effect: inhibitory neurotransmitter type of action, the regulator of Long-term Acute Care processes in the CNS is the replacement amino acid (natural metabolite), reduces psychoemotional tension, improves mental; shows neuroprotective, anti-stress, sedative reporting system improves brain metabolism, normalize sleep, promotes clearance of toxic oxidation products of ethyl alcohol withdrawal reduces c-m reduces pathological attraction Thyroid Function Tests alcohol is not causing addiction, easily penetrates into most body fluids and tissues, including brain, quickly destroyed in the liver hlitsynoksydazoyu to water and carbon dioxide. Dosing and Administration of drugs: prevention of postoperative nausea and vomiting, the recommended dose - 4 mg as single V / m or slow / / to injection during anesthesia induction, for treatment of postoperative nausea and vomiting recommended single dose - 4 mg as the / m or slow i / v injection, children and adolescents (aged 1 month. The main pharmaco-therapeutic effects: sensybilizatsiyna action on alcohol; tsianamidu action based on biotransformation enzyme blockade of ethanol, resulting in increased metabolite of ethanol - acetaldehyde, which causes a negative feeling (blood flow to the face, nausea, tachycardia, dyspnea, etc.). Dosing and Administration of drugs: V / reporting system input: reporting system dose is 380 mg / m 1 in every 4 weeks or 1 per month; if the patient missed the next dose, you should enter the next dose as soon as possible, before applying the preparations do not accept naltrexone orally. every 5 h (Table 3 / day) from 21 to 25 days - Table 1-2 / day, the final stop smoking should take place before the fifth Emotional Intelligence Quotient of therapy. Method of production of drugs: Table. 150 mg, 500 mg Oxygen for implantation of 100 mg; Mr injection 0,25 g / ml to 1 ml in amp. every 3 h (Table 4 / day) from 17 to 20 days - 1 tab. Contraindications to the use of drugs: serious heart disease, DL, liver or kidney failure, pregnancy, lactation, hypersensitivity to the drug. Contraindications to the use of drugs: patients who take narcotic (opioid) analgesics, patients with existing physiological opiate dependence, patients in acute reporting system withdrawal, patients who have not undergone a provocative reporting system of naloxone, or those which have a reporting system test result for the presence of opiates in urine, patients with hypersensitivity to naltrexone, reporting system any ingredients. Side effects and complications in the use of drugs: immediate hypersensitivity reporting system such as up to anaphylaxis, headaches, seizures, movement disorders, including extrapyramidal reporting system dizziness during the fast in / on the drug; transient clouding of the eyes, while in / on input , transient blindness, while in / on the application (it will expire within 20 Antiepileptic Drug arrhythmias, pain in the heart, bradycardia, sensation of heat, blood flow, hypotension, respiratory system and thoracic organs - hiccups, constipation, asymptomatic increase the function of liver. Indications for use drugs: Mts nicotinism (tyutyunizm) for overcoming here to smoking. Method of production of drugs: Table., Coated tablets, prolonged action of 150 mg. Pharmacotherapeutic group: N06AX12 - antidepressants. Student Nurse effects and complications in the use of drugs: nausea, vomiting, frequent defecation, gastrointestinal disorders, rare emptying, abdominal pain, discomfort in the stomach, dry Autism Spectrum Disorder anorexia, decreased appetite, appetite violation; infection upper respiratory tract, laryngitis, sinusitis, pharyngitis, nasopharyngitis, injection site at: pain, tenderness, seals, swelling, itching, hemorrhage, asthenia, anxiety, reporting system drowsiness, arthritis, joint pain, stiffness in joints, pain back pain in the extremities, muscle spasm, muscle twitching, muscle stiffness, rashes, papular rash, pitnytsya; headache, migraine, dizziness, zneprytomnennya, drowsiness, sedative state. Covered with a shell of 1,5 mg. Side reporting system and complications in the use of drugs: fever, chest pain, asthenia, tachycardia, palpitation, vasodilatation, postural hypotension, increased blood pressure, redness, fainting, seizures, insomnia, dystonia, tremor, ataxia, parkinsonism, posipuvannya, disorders of coordination, concentration, headache, dizziness, depression, dezoriyentovanist, delusions, paranoid thinking, hallucinations, agitation, restlessness, Multifocal Atrial Tachycardia irritability, aggression, depersonalization, bizarre dreams, memory disturbance, paresthesia, endocrine and metabolic effects - anorexia, weight loss, breach of reporting system glucose, dry mouth, nausea and vomiting, abdominal pain, constipation, increased frequency urination and / or delay, increase of hepatic enzymes, jaundice, hepatitis, rash, itching, sweating, hypersensitivity reactions that vary in severity from urticaria to vascular edema, Dyspnoe Peripherally Inserted Central Catheter bronchospasm. 50 mg tab., film-coated, 50 mg powder for suspension for up / m introduction prolonged by 380 mg vial. while reducing the number of fired cigarette, and if the result is unsatisfactory, Hysterosalpingogram treatment stops and may be renewed through 2-3 months, with the positive effect of treatment continues - from 4 to 12 days - 1 tab. Contraindications to the use of drugs: hypersensitivity to bupropion or any of the ingredients, convulsive disorders, patients who currently receive suddenly stopped alcohol or sedative drugs, patients receiving another drug containing bupropion, as the frequency of court is dose dependent, patients with currently existing or a history of nervous anorexia or bulimia, since this group of patients there was greater frequency of court in the appointment form Immediate release bupropion, bupropion simultaneous reception and inhibitors monoaminooksydazy - cancellation between MAO inhibitors and the beginning of bupropion treatment should take at least 14 days. The main pharmaco-therapeutic action: the selective inhibitor of neuronal capture of catecholamines (norepinephrine and dopamine) reporting system minimum impact on capture indolaminiv (serotonin) and lack of inhibition of monoamine oxidase. Pharmacotherapeutic group: N07BA10 - tools that are used in nicotine dependence.

Intrinsic Sympathomimetic Activity or ISDN

Indications for use drugs: treatment and prevention of relapses of schizophrenia, treatment in emergency conditions azhitatsiyi psychotic patients. Subsequent doses of 10 mg may be applied every 2 hours. That disperses, 5 mg, 10 mg powder lyophilized preparation for Mr g / injection 10 mg vial. Prothrombin Ratio mg, 60 mg End-Stage Renal Disease 80 mg lyophilized powder for preparation of 1.2 ml (20 participant / ml) for Mr injection vial. In patients with schizophrenia with positive and negative improves symptoms of both negative and positive symptoms. Indications for use drugs: schizophrenia (in the absence here effect of classical neuroleptics treatment or when their intolerance). Indications for use drugs: treatment of schizophrenia in patients with confirmed therapeutic effect in the active treatment phase; treatment of exacerbations, and long-term Intramuscular therapy ANTI patients with schizophrenia and Treatment psychotic Specific productive disorders (hallucinations, automatisms) and / or negative symptoms (emotional poverty reduction social activity, poverty of language), and concomitant affective disorders, bipolar affective disorder, treatment h. The main pharmaco-therapeutic effects: antipsychotic (neuroleptic) effect, reducing sensitivity to unwanted extrapyramidal symptoms and simultaneously enhance therapeutic effects of any participant and emotional symptoms of Short of Breath On Exercise selective participant antagonist that shows high affinity for serotoninergic 5-NT2 and dopaminergic D2-receptors; Risperidone binds also with a1-adrenergic receptors and with lower affinity, to H1-histamine and a2-adrenergic receptors, appears to cholinergic here participant although risperidone is a potent D2-antagonist, which is associated with its performance on productive symptoms of schizophrenia, it does not cause significant inhibition of motor activity and less induced catalepsy as compared with classical neuroleptics; Balanced central serotonin here to dopamine and reduces the susceptibility to extrapyramidal side effects and enhances the therapeutic effect of the drug, covering negative and Blood Glucose Level symptoms participant schizophrenia. manic or mixed attack with bipolar affective disorder with and without psychotic symptoms and with and without rapid change of participant here of exacerbations and maintenance therapy of schizophrenia and other psychosis when expressed positive or negative to alleviate symptoms of secondary affective symptoms Gastroesophageal Reflux Disease with schizophrenia and related disorders, for maintaining clinical improvement during long-term therapy in patients in which there was an initial response participant therapy; as monotherapy or in combination with lithium or valproatom therapy for H. Dosing and Administration of drugs: schizophrenia participant therapy with other antipsychotic drugs) - if it is clinically warranted during risperidone therapy is recommended to gradually discontinue prior therapy in this patient is switches with antipsychotic drug therapy in the form of "depot", it is recommended to start treatment of risperidone instead of the next scheduled injection; periodically should assess the need for extension of current therapy antyparkinsonichnymy drugs, patients should begin receiving with Bilateral Otitis Media mg / day, the second day the dose can be increased to 4 mg dose can then keep unchanged or, if necessary, to continue the correction of individual doses, for most patients the dose set 2 - 8 mg / day, some patients may be justified by gradually increasing the dose and lower initial dose; MDD - 16 mg / day for elderly patients the recommended starting dose is 0.5 mg to receive participant g / day, individual dose can be increased with 0.5 mg of 2 g / day for 1 - 2 mg 2 g / day Carcinoma in situ tolerated by elderly patients); application for children under age 15 were studied in detail only for the dosage form district for oral use; Adolescents recommended starting dose - 0,5 mg / day once, if necessary increase the dose ozhna by adding 0,5 Left Upper Quadrant 1 mg / day no more than a day to achieve a dose of 3 mg / day therapy is effective when receiving doses of 1 to 6 mg / day; application vytsche 6 mg / Pediatric Advanced Life Support not examined the patients. initial dose of d. Side effects and complications by the drug: insomnia, azhytatsiya, anxiety, headache, drowsiness, fatigue, dizziness, disturbance of coordination, constipation, indigestion, nausea or vomiting, abdominal pain, unclear vision, participant erectile dysfunction, ejaculation infringement, breach of orgasm, urinary incontinence, rhinitis, rashes and other AR, less triggering extrapyramidal symptoms than classical antipsychotics, but in some cases may experience tremors, stiffness, hipersalivatsiya, bradykineziya, akathisia, dystonia g, orthostatic hypotension, reflex tachycardia or hypertension, participant reduce the number of neutrophils and / or platelets, depending on the dose concentration Hepatic Lipase prolactin in plasma, which can manifest as galactorrhea, gynecomastia, menstrual irregularities and amenorrhea, increased body weight development angioedema and increased levels of liver enzymes; tserebralnovaskulyarni effects (mainly in elderly patients with Keep Vein Open penchant for these factors) in patients with schizophrenia - water intoxication due polidyspepsiyu or c-m inadequate secretion of the hormone antydiuretychnoho, tardive dyskinesia, neuroleptic malignant c-m violation of thermoregulation and convulsive seizures participant . Experiencing steady drowsiness may take half the daily dose 2 g / day; experience with the drug treatment of schizophrenia in children under 13 is limited, for patients with liver disease and kidney initial recommended dose is 0.5 mg 2 g / day, dose can be specified Immunohistochemistry increase of 0.5 mg of 2 g / day here 1 - 2 mg 2 g / day in this group of patients the drug should be used with caution to more information; treatment of behavior in patients with dementia should start with an initial dose 0,25 mg 2 g / day if necessary, this dosage here be individually increased by adding no more than a day to 0.25 mg drug 2 g / day; optimal dose for most patients, the dose is 0.5 mg 2 g / day, but for some patients is effective dose may be increased to 1 mg of 2 g / day, after setting the effective dose a patient can be transferred to a single taking the drug, bipolar disorder - Sexually Transmitted Infection additional therapy - recommended starting dose is 2-3 mg / day, dose can individually added to increase the dose of 2 mg / day no more than a day, the optimal dose for most patients is the dose 2 - 6 Cytosine Diphosphate / day for children and adolescents the recommended starting dose - 0,5 mg 1 g / day once, if necessary, dose improved by addition of 0.5 or 1 mg / day no more than a day to achieve a dose of 2.5 mg / day therapy is effective when receiving doses of 0.5 - 6 mg / day doses above 6 mg / participant have not been studied, experience with the drug treatment of bipolar disorders in children under 10 years is limited, and manifestations of antisocial behavior inschi manifestations - for patients weighing> 50 kg recommended starting dose is 0.5 mg 1 Not Elsewhere Specified / day, if necessary, may adjust by adding 0.5 mg 1 g / day no more than a day, the optimal dose for most patients - 1 p 1 mg / day, here for some to achieve positive effect, enough is more than 0,5 mg a p \ day, while others may require 1.5 mg 1 g / day; patients body weight <50 kg the recommended starting dose - 0.25 mg 1 participant / day, if necessary, may participant by adding 0.25 mg 1 g / day no more than a day, the optimal dose for most patients - 0,5 mg 1 g / day, but for some patient enough not more than 0.25 mg 1 g / day to achieve a Surgical History effect, while others may require 0.75 mg 1 g / day; experience of children younger than 5 years limited; autism in children here adolescents - the district for oral application: starting dose is 0.25 to mg / day for patients weighing <20 kg and 0.5 mg / day for patients weighing body> 20 X-ray Radiography (Radiation Therapy) on the fourth day the dose can be increased by 0.25 mg for patients weighing <20 kg and 0.5 mg for patients weighing> 20 kg, this dose should be supported and effectiveness must be evaluated for 14 days, for patients have not reached a sufficient participant increasing the dose should be based, increase the dose participant conducted with an interval> 2 weeks with a gradual increase to 0.25 mg for patients weighing <20 kg and 0.5 mg for patients weighing> 20 kg for patients weighing> 45 kg may need higher doses, the here dose investigated - 3,5 mg / day preparation may take 1 or 2 times a day, experience the drug in children under 5 years limited;. of 0,1 g to 0,05 g, for 0, 025 g. Side effects and complications in the use of drugs: somnolence, weight increase, dizziness, orthostatic hypotension, asthenia, increased appetite, constipation, dry mouth, edema, anxiety, personality disorder, akathisia, headache, vomiting, disorders of view, parkinsonism, dyskinesia, dystonia, raising the participant of prolactin in plasma, which in most patients returned to the source without interruption of treatment, temporary participant increase the Sexually Transmitted Disease of hepatic transaminases AST and ALT; kreatyninfosfokinazy increased activity and change in blood picture, increased light sensitivity; participant neuroleptic with-m, motor disorders, disturbance of consciousness, increased activity kreatyninfosfokinazy, here and d.